Evidence map›Paper›PMID 41211450›Full record

ArticleFrontiers in oncology2025

Case Report: Dual resistance to dasatinib/olverembatinib in accelerated-phase cml: identification of a novel

Jingjing Fu, Yangming Tang, Xueqin Ruan, Runfa Wang, Tong Chen, Li Jiang, Yanli He, Zhihong Xu, Balian Wang, Haiqin Zhang and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jingjing FuThe Department of Cytogenetics, Kindstar Globalgene Technology, Inc, Wuhan, China.
Yangming TangThe Department of Hematology, Guangxi Academy of Medical Sciences & The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Xueqin RuanThe Department of Hematology, Guangxi Academy of Medical Sciences & The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Runfa WangThe Department of Cytogenetics, Kindstar Globalgene Technology, Inc, Wuhan, China.
Tong ChenThe Department of Cytogenetics, Kindstar Globalgene Technology, Inc, Wuhan, China.
Li JiangThe Department of Cytogenetics, Kindstar Globalgene Technology, Inc, Wuhan, China.
Yanli HeCenter for Stem Cell Research and Application, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhihong XuThe Department of Cytogenetics, Kindstar Globalgene Technology, Inc, Wuhan, China.
Balian WangThe Department of Hematology, Guangxi Academy of Medical Sciences & The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Haiqin ZhangThe Department of Cytogenetics, Kindstar Globalgene Technology, Inc, Wuhan, China.
Jing ZhouThe Department of Cytogenetics, Kindstar Globalgene Technology, Inc, Wuhan, China.
Mei Lan *The Department of Hematology, Guangxi Academy of Medical Sciences & The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Hongrui Li *The Department of Cytogenetics, Kindstar Globalgene Technology, Inc, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In chronic myeloid leukemia (CML), less than 2% of cases express atypical or rare

Indexed as

accelerated phaseBCR::ABL1chronic myeloid leukemia (CML)e8a2SPECC1LV379I mutation

Identifiers

PMID41211450
PMCPMC12591956

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.